praliciguat

Praliciguat is a small molecule soluble guanylate cyclase (sGC) stimulator developed for the treatment of cardiovascular and metabolic diseases, including heart failure with preserved ejection fraction (HFpEF) and diabetic nephropathy. It amplifies nitric oxide signaling by directly stimulating sGC, leading to increased production of cyclic guanosine monophosphate (cGMP). This results in vasodilation, anti-inflammatory, antifibrotic, and antihypertensive effects. Praliciguat has shown beneficial effects in preclinical models by preserving cardiac function, reducing kidney inflammation and fibrosis, lowering blood pressure, and improving metabolic parameters such as glucose and cholesterol levels. The drug was initially developed by Ironwood Pharmaceuticals and later advanced by Cyclerion Therapeutics; Akebia Therapeutics has also been involved in its development[1][4][5][6][7].

Other names

praliciguat [INN]